Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Accenture
Daiichi Sankyo
Covington
Cipla
Teva
Baxter
Chubb
Citi

Generated: December 19, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LYRICA CR

« Back to Dashboard

Clinical Trials for Lyrica Cr

Trial ID Title Status Sponsor Phase Summary
NCT00280059 Study Of The Safety And Efficacy Of Lyrica In The Treatment Of Newly Diagnosed Partial Epilepsy Completed Pfizer Phase 3 The purpose of this study is to assess whether Lyrica is a safe and effective treatment for partial epilepsy in comparison with an established treatment, Lamictal.
NCT00288639 Lyrica (Pregabalin) Administered as an Add-on Therapy for Partial Seizures (LEADER). Completed Pfizer Phase 4 The objective of study is to assess the clinical improvement (change in seizure frequency), safety, and tolerability of subjects with partial seizures following adjunctive therapy of pregabalin BID (150 to 600 mg/day titration) in addition to existing standards AEDs.
NCT00291148 Neuropathic Pain Assessment Comparing Pregabalin and Paroxetine in Management of MS-induced Neuropathic Pain Completed University of Manitoba Phase 3 This is a comparative drug trial involving patients with clinically definite Multiple Sclerosis and documented neuropathic pain. Patients will be randomized to receive treatment with either paroxetine or pregabalin. After dose titration, participants will complete various pain scale assessments at several points during the study in order to determine the effectiveness of their assigned pain medication.
NCT00351611 Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo Recruiting Pfizer Phase 4 Patients with partial seizures currently taking 1-3 antiepileptic medications will have a 50:50 chance to receive Lyrica 300 mg per day or placebo (no active ingredients) added on to their current medications for 3 months. Neither the study doctor nor the patient will know the medication assignment. Vision testing will be performed prior to receiving the study treatment and at the end of the study to see if there are any changes.
NCT00352651 Study to Find Out if Therapy With the Drug Pregabalin Relieves Pain During Shingles Compared With Placebo Terminated Pfizer Phase 2 The purpose of this study is to see if therapy with the drug pregabalin relieves pain during shingles compared with placebo. A placebo is an inactive substance. Pregabalin is a drug marketed as Lyrica™ in the United States for the treatment of seizures, diabetic neuropathy, and post-herpetic neuralgia. The use of pregabalin and drugs like it for the treatment of pain during the acute phase of shingles is experimental. Thirty four subjects will complete the study at the University of California, San Francisco (UCSF) Pain Clinical Research Center. This study is funded by Pfizer Global Research.
NCT00352651 Study to Find Out if Therapy With the Drug Pregabalin Relieves Pain During Shingles Compared With Placebo Terminated University of California, San Francisco Phase 2 The purpose of this study is to see if therapy with the drug pregabalin relieves pain during shingles compared with placebo. A placebo is an inactive substance. Pregabalin is a drug marketed as Lyrica™ in the United States for the treatment of seizures, diabetic neuropathy, and post-herpetic neuralgia. The use of pregabalin and drugs like it for the treatment of pain during the acute phase of shingles is experimental. Thirty four subjects will complete the study at the University of California, San Francisco (UCSF) Pain Clinical Research Center. This study is funded by Pfizer Global Research.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Lyrica Cr

Condition Name

Condition Name for Lyrica Cr
Intervention Trials
Healthy 9
Epilepsy 5
Neuropathic Pain 5
Fibromyalgia 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Lyrica Cr
Intervention Trials
Neuralgia 16
Diabetic Neuropathies 8
Peripheral Nervous System Diseases 7
Epilepsy 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Lyrica Cr

Trials by Country

Trials by Country for Lyrica Cr
Location Trials
United States 304
India 24
Canada 21
China 16
Korea, Republic of 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Lyrica Cr
Location Trials
Florida 16
Texas 15
California 14
North Carolina 13
Georgia 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Lyrica Cr

Clinical Trial Phase

Clinical Trial Phase for Lyrica Cr
Clinical Trial Phase Trials
Phase 4 21
Phase 3 22
Phase 2/Phase 3 1
[disabled in preview] 22
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Lyrica Cr
Clinical Trial Phase Trials
Completed 46
Recruiting 9
Terminated 7
[disabled in preview] 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Lyrica Cr

Sponsor Name

Sponsor Name for Lyrica Cr
Sponsor Trials
Pfizer 36
GL Pharm Tech Corporation 4
Hospital for Special Surgery, New York 2
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Lyrica Cr
Sponsor Trials
Industry 54
Other 43
NIH 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Express Scripts
Daiichi Sankyo
US Army
Harvard Business School
McKinsey
Cerilliant
Chubb
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.